Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

The Oncologist
F MontemurroM Aglietta

Abstract

We sought to describe patterns of treatment and clinical outcome in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy. One hundred eighty-four consecutive HER2-positive advanced breast cancer patients received trastuzumab-based therapy between September 1999 and September 2004. Patients were followed up until death or May 2005. For patients progressing on trastuzumab-based therapy, we calculated the response rate (RR) to the first post-progression treatment, overall survival (OS) from the first administration of trastuzumab, time to second progression (TT-SP), and post-progression survival (PPS), according to treatment. At the time of this analysis, 132 patients had progressed on trastuzumab-based therapy, and 89 had died. Of the progressing patients, 21 experienced rapid progression and could not receive additional anticancer treatments;40 patients continued trastuzumab either alone (12 patients with isolated central nervous system progression), with chemotherapy (23 patients), or with endocrine therapy (5 patients); and 71 stopped trastuzumab and received chemotherapy (61 patients) or endocrine therapy (10 patients) as the first post-progression treatment. Excluding patients with rapi...Continue Reading

References

Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Leyland-JonesA Rakhit
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debu TripathyStanford J Stewart
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
Mar 1, 2005·Oncogene·Giorgio ValabregaSilvia Giordano
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Filippo MontemurroMassimo Aglietta
Apr 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NorumJ A Olsen
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark

❮ Previous
Next ❯

Citations

May 25, 2010·Archives of Gynecology and Obstetrics·Umut KefeliMahmut Gumus
Jun 6, 2007·Nature Clinical Practice. Oncology·Filippo Montemurro, Massimo Aglietta
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Mar 17, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y WuH J Burstein
Nov 1, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S GoriD Crivellari
Dec 17, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J D JensenM Ewertz
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M CapelanM J Piccart-Gebhart
Jun 15, 2010·Japanese Journal of Clinical Oncology·Charles VogelHanlim Moon
Apr 3, 2012·Nucleic Acids Research·Kristina W ThielPaloma H Giangrande
Jul 3, 2010·Journal of Gastroenterology and Hepatology·Xin-Xin ZhouCheng-Fu Xu
Jul 18, 2008·Breast Cancer Research : BCR·Giuseppe CancelloMichele De Laurentiis
Jun 26, 2010·The Oncologist·Filippo MontemurroMassimo Aglietta
Jul 31, 2010·The Oncologist·Rinat Yerushalmi, Karen Gelmon
Mar 12, 2011·The Oncologist·Filippo MontemurroMassimo Aglietta
Feb 26, 2015·Current Opinion in Oncology·Philippe BarthélémyAhmad Awada
Sep 15, 2010·Expert Review of Anticancer Therapy·Gerald M HigaJame Abraham
Feb 6, 2010·Expert Review of Anticancer Therapy·Alba A BrandesRoberta Degli Esposti
Sep 26, 2007·Expert Review of Anticancer Therapy·Gerald M Higa, Jame Abraham
Jan 26, 2007·Expert Opinion on Biological Therapy·Filippo MontemurroMassimo Aglietta
Sep 19, 2009·Expert Opinion on Pharmacotherapy·Gerald M Higa
Aug 30, 2011·Cancer Treatment Reviews·Javier Cortes, Henri Roché
Dec 3, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Marta RossiEva Negri
Sep 15, 2009·Cancer Treatment Reviews·D CollinsL Young
Dec 2, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Peter S Hall, David A Cameron
Nov 15, 2008·Cancer Treatment Reviews·Dorte Lisbet NielsenClaus Kamby
Sep 5, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A NicoliniP Miccoli
Oct 7, 2015·Current Pharmacology Reports·Joseph Wahler, Nanjoo Suh
Jul 3, 2015·Protein Engineering, Design & Selection : PEDS·Gillian HoulihanFlorian Hollfelder
Jun 12, 2013·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Junichi KurebayashiHiroshi Sonoo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Debu TripathyStanford J Stewart
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Charles L VogelMichael Press
The New England Journal of Medicine
Charles E GeyerDavid Cameron
© 2022 Meta ULC. All rights reserved